Published in Thromb J on June 23, 2014
Opportunistic screening for atrial fibrillation in a rural area. QJM (2016) 0.78
Contemporary approaches to managing atrial fibrillation: A survey of Australian general practitioners. Australas Med J (2015) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med (2000) 5.41
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15
Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol (2009) 3.68
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ (2006) 2.71
Surveying physicians: do components of the "Total Design Approach" to optimizing survey response rates apply to physicians? Med Care (2002) 2.68
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke (2000) 2.29
Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med (1996) 2.13
Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc (1997) 2.09
Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med (1999) 2.07
Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med (2013) 2.00
Availability, wishful thinking, and physicians' diagnostic judgments for patients with suspected bacteremia. Med Decis Making (1991) 1.94
Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing (2011) 1.94
Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke (2007) 1.91
Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med (2003) 1.85
Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol (2002) 1.69
Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing. Age Ageing (2002) 1.55
Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med (2006) 1.40
Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med (1998) 1.33
The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol (2003) 1.25
Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ (2001) 1.13
Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J (2002) 1.12
Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther (2003) 1.10
Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol (2007) 1.09
Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract (2012) 1.07
What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire. J Thromb Thrombolysis (2006) 1.02
Use of warfarin in long-term care: a systematic review. BMC Geriatr (2012) 0.98
'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM (2007) 0.93
Oral anticoagulation in atrial fibrillation: A pan-European patient survey. Eur J Intern Med (2007) 0.93
Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences. Can J Clin Pharmacol (2002) 0.93
Do physician outcome judgments and judgment biases contribute to inappropriate use of treatments? Study protocol. Implement Sci (2007) 0.87
Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke (2007) 0.85
Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation. Stroke (2010) 0.78
Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc (2012) 0.78
Barriers to using warfarin in non-valvular atrial fibrillation. BMJ (2006) 0.77
Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. J Thromb Haemost (2013) 0.77
Anticoagulation for atrial fibrillation: underuse? Am J Med (2011) 0.76